{"entity":{"id":"nct07803783","kind":"trial","name":"A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based","aka":[],"tldr":"A phase 3 trial of YL201, liposomal irinotecan, fluorouracil (5-FU) and fLOT (5-FU, leucovorin, oxaliplatin, docetaxel) in pancreatic cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., not yet recruiting.","summary":"A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy is a phase 3, randomised interventional study registered as NCT07803783 by MediLink Therapeutics (Suzhou) Co., Ltd., with a registry enrolment figure of 320 participants, started 2026-10 and due to reach its primary completion in 2029-01. Interventions recorded: Tambotatug pelitecan; Liposomal irinotecan; 5 Fluorouracil; Leucovorin. Conditions listed: Metastatic Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma (PDAC). Primary outcome: PFS by BICR; OS. Pancreatic eligibility wording from the registry: \"Participants must have histologically or cytologically confirmed incurable metastatic pancreatic ductal adenocarcinoma (PDAC)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07803783","url":"https://clinicaltrials.gov/study/NCT07803783"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["yl201","liposomal-irinotecan","fluorouracil","flot"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07803783","phase":"3","setting":"A Randomized, Controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of YL201 Versus Liposomal Irinotecan in Combination With 5-Fluorouracil/Leucovorin in Participants With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed Prior Gemcitabine-based Systemic Therapy","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","enrolled":320,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07803783/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/"},{"id":"yl201","kind":"drug","name":"YL201","route":"/drugs/yl201/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}